The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms

Yuxia Songa,b *, Hongyang Fanb, Xiaojia Tanga,b, Yuhan Luo*a,b, Peipei Liub,c and Yingzhu Chenb,c

aDepartment of Neurology, Dalian Medical University, Dalian, Liaoning, China; bDepartment of Neurology, Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu, China; cDepartment of Neurology, Northern Jiangsu People’s Hospital, Yangzhou, Jiangsu, China

ABSTRACT

Purpose: As of November 28, 2020, COVID-19 has been reported in 220 countries with 61,036,793 confirmed cases and 1,433,316 confirmed deaths; countries became vigilant around the world. In addition to SARS-CoV-2 causing pneumonia, many studies have reported ischemic stroke in patients with COVID-19. This article describes the effects and possible underlying mechanisms of SARS-CoV-2 on ischemic stroke.

Materials and methods: A literature search was performed using PubMed, Web of Science, and other COVID-dedicated databases and the combination of the keywords ‘SARS-CoV-2’, ‘COVID-19’ and ‘ischemic stroke’ up to November 28, 2020.

Results: SARS-CoV-2 invades the host through angiotensin converting enzyme 2 (ACE2). ACE2 is expressed not only in the lungs, but also in the brain and vascular endothelial cells. SARS-CoV-2 infection might cause direct vascular disease or enhance the immunogenic thrombosis environment through several mechanisms. SARS-CoV-2 infection can modulate the host immune response and can cause inflammation, coagulation disorders, renin angiotensin system disorders, hypoxia, and stress disorders, which may lead to the occurrence of ischemic stroke.

Conclusions: Some patients with COVID-19 can develop ischemic stroke. Ischemic stroke has a high risk of causing disability and is associated with a high mortality rate. It is hoped that when medical staff treat patients with COVID-19, they would pay attention to the occurrence of ischemic stroke to improve the prognosis of patients with COVID-19.

Introduction

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection occurred in Wuhan, China with many cases in the ‘South China Seafood Market’ [1]. SARS-CoV-2 was previously temporarily named 2019-nCoV [2]. On February 11, 2020, the World Health Organization (WHO) announced a new name for the epidemic caused by SARS-CoV-2: coronavirus disease 2019 (COVID-19). COVID-19 was declared as a ‘public health emergency of international concern’ by the WHO on January 30, 2020. And COVID-19 is spreading rapidly. As of November 28, 2020, COVID-19 has been reported in 220 countries with 61,036,793 confirmed cases and 1,433,316 confirmed deaths; nowadays, countries are vigilant around the world [3].

A series of case studies showed that all six patients included showed no or mild COVID-19 symptoms, and five of the six patients (83%) had stroke symptoms as the initial and main symptoms, indicating that even mild symptoms can lead to strokes [4]. There is increasing evidence that ischemic stroke and COVID-19 are related to each other. Approximately 5% patients with severe COVID-19 infection and 1% patients with non-severe infections develop ischemic stroke [5]. In addition, stroke is associated with a 2.5-fold increase in the likelihood of severe COVID-19, with a trend for increased mortality [6]. A literature search was performed using PubMed, Web of Science, and other COVID-dedicated databases and the combination of the keywords ‘SARS-CoV-2’, ‘COVID-19’ and ‘ischemic stroke’ up to November 28, 2020. Therefore, this article describes the effects and possible underlying mechanisms of SARS-CoV-2 on ischemic stroke with the aim that medical staff should pay attention to the possibility of ischemic stroke when treating patients with COVID-19.
**Virology and pathogenesis**

In recent years, outbreaks of coronavirus infection have occurred sporadically. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection was first detected in 2002, and middle east respiratory syndrome coronavirus (MERS-CoV) infection was first detected in 2012 [7]. Coronavirus can cause respiratory and intestinal infections in animals and humans. Previous coronaviruses transmitted to humans mainly caused minor symptoms. After the outbreak of severe acute respiratory syndrome (SARS) in 2002, coronavirus was considered highly pathogenic to humans [8–10]. SARS-CoV-2 (subgenus Sarbecovirus, subfamily Orthocoronavirinae) is a new beta coronavirus containing a non-segmented, positive-sense RNA [11]. The SARS-CoV-2 viral sequence is very similar to the bat coronavirus sequence (overall genome sequence identity of 96.2%). In addition, its sequence homology with SARS-CoV is also as high as 79.5% [12]. According to the viral genome sequencing results and evolutionary analysis, SARS-CoV-2 originated from bats and may have been transmitted to humans through multiple intermediate hosts [13]. The spike glycoprotein of SARS-CoV-2 binds to host cells via angiotensin-converting enzyme 2 (ACE2), fuses with membranes, and releases viral RNA [14]. Viral RNA functions as a pathogen-associated molecular pattern and is detected by the pattern recognition receptors (PRRs) to induce the host immune response.

**Immune response**

When SARS-CoV-2 invades a host, the host’s innate immune system uses PRRs, mainly Toll-like receptor (TLR), retinoic acid-inducible gene-I-like receptor, and nucleotide-binding oligomerization domain-like receptor [15], which recognize viral nucleic acids, collect specific signal adapter proteins, activate interferon-regulatory factor (IRF) 3 and IRF7, and translocate to the nucleus to promote the synthesis of type I Interferons (IFNs). IFNs then activate the downstream JAK-STAT signaling pathways and promote the expression of interferon-stimulated genes [16]. IFNs, the host’s main antiviral molecule, can limit the spread of the virus, exert immunomodulatory effects, promote the phagocytosis of antigens by macrophages, and kill the infected target cells by natural killer cells.

In addition, the adaptive immunity of the patient also plays an important role in antiviral activity. Depletion of CD4+ T cells is associated with reduced recruitment of lymphocytes in the lungs and reduced production of neutralizing antibodies and cytokines, leading to strong immune-mediated interstitial pneumonia and delayed viral clearance from the lungs [17]. T helper cells produce pro-inflammatory cytokines through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway [18]. Interleukin (IL)-17 recruits monocytes and neutrophils to sites of infection and activates downstream cytokine and chemokine cascades producing IL-1, IL-6, IL-8, IL-21, tumor necrosis factor (TNF)-β, and monocyte chemoattractant protein-1 (MCP-1) [19]. C3a and C5a have strong pro-inflammatory effects, which can stimulate the recruitment of inflammatory cells and the activation of neutrophils, thereby triggering a series of innate immune response-related antiviral effects and the increase in the production of inflammatory cytokines. The increase of inflammatory cytokines is related to a more serious prognosis [20].

**Possible mechanisms**

1. **Inflammation and coagulation disorders**

   After SARS-CoV-2 invasion, pathogen-associated antigens not only combine with immune cells to produce inflammatory cytokines but also bind to PRRs, such as TLR4, expressed on endothelial cells and platelets, thereby triggering a series of innate immune and prothrombotic events [21]. A large amount of evidence indicates that patients with severe COVID-19 experience a cytokine storm and the stronger the cytokine storm, the more severe the symptoms [22, 23]. Cytokine storm refers to the excessive release of C-reactive protein (CRP) and pro-inflammatory cytokines, such as TNF-α, IL-8, IL-6, which can cause severe coagulation disorders [23, 24]. One of the characteristics of severe COVID-19 is ‘sepsis-induced coagulopathy (SIC)’. SIC is associated with a systemic inflammatory response to infection and is a precursor to disseminated intravascular coagulation, which is associated with elevated prothrombin time, elevated D-dimer, and thrombocytopenia but not with hypofibrinogenemia [25–27]. SIC may also cause endothelial dysfunction, microthrombus formation, and stroke [27].

   During infection, platelets, coagulation factors, and other components of the immune system can interact to form clots; this process is known as immune thrombosis (also known as thrombotic inflammation) [28, 29]. After SARS-CoV-2 infection, a large number of pro-inflammatory cytokines are produced through a series of immune responses. T lymphocytes [30], IL-6, and TNF-α may cause microvascular damage [31]. TNF-α can
promote overexpression of tissue factor (TF) on platelets and macrophages [32]. The production of anti-phospholipid COVID-19 antibodies can also upregulate TF expression [32]. TF is a transmembrane protein that can be used as a high-affinity receptor and cofactor for coagulation factors VII and VIIa [33]. It forms a part of a key step in the activation of the coagulation system during infection [34]. Proinflammatory cytokines, such as IL-1β, IL 6, and TNF-α, can promote the release of ultra-long von Willebrand factor (VWF) multimers and produce TF and coagulation factors VII/VIIa. This leads to increased thrombin generation, reduced endogenous anticoagulant levels of tissue factor pathway inhibitor, antithrombin, and activated protein C [35]. In addition, complement C3a and C5a can activate platelets and endothelial cells as well as increase the expression of TF and VWF [36]. P-selectin from storage granules is upregulated on the surface of activated platelets to promote interaction with recruited neutrophils, thereby forming platelet-neutrophil complexes [37]. SARS-CoV-2 upregulates the hfgl2 prothrombinase gene, which may further promote thrombin generation and hypercoagulability in COVID-19 [38]. In addition to causing abnormal coagulation, inflammatory cells, mainly monocytes and/or macrophages, begin to accumulate early in the walls of blood vessels to promote the formation of atherosclerosis. In the later stages of the disease, their activation can cause plaque rupture and thrombosis that increases the risk of ischemic stroke [39]. Studies show that monomeric CRP has atherogenic and thrombogenic properties, because it interacts with other immune mediators to activate platelets and complement proteins [40]. IL-6 is the main driving force that regulates the production of CRP in the liver. It also mediates the formation of atherosclerosis associated with classic risk factors such as aging, hypertension, smoking, and obesity [41]. Large-sample studies have shown that CRP and IL-6 are associated with ischemic stroke [42, 43].

2. Renin angiotensin system disorders

SARS-CoV-2 infects humans by binding with angiotensin-converting enzyme 2 (ACE2) [44]. ACE2 is widely expressed in various tissues of the human body, especially in cardiovascular system [45, 46]. ACE2 is also expressed in the brain at lower levels [47]. The expression and distribution of ACE2 suggest that SARS-CoV-2 can cause ischemic stroke indirectly by acting on the cardiovascular system and directly by acting on the brain.

Researchers have found that the cerebrospinal fluid of some patients with COVID-19 tested positive for SARS-CoV-2 by polymerase chain reaction [48], and SARS-CoV-2 was also detected in their brains by autopsy [49]. Like other respiratory viruses, SARS-CoV-2 can enter the central nervous system through blood or retrograde neuronal pathways (the fact that about 70% patients with COVID-19 have olfactory and/or taste disorders supports the latter point [50]). All components of renin-angiotensin system (RAS), including angiotensinogen, ACE, ACE2, and angiotensin II (Ang II) receptors, are expressed in the brain [47, 51]. RAS usually refers to the conversion of angiotensinogen to angiotensin I (Ang I) by renin. Later, Ang I is cleaved into Ang II by ACE to interact with Ang II type 1 (AT1) and Ang II type 2 (AT2) receptors [52]. RAS is one of the most important systems in the pathogenesis of cardiovascular and cerebrovascular diseases. The distribution of ACE2 in the brain is mainly in cerebral microvascular endothelial cells and astrocytes [53]. This indicates that SARS-CoV-2 might bind to this protein in the brain and cause cerebral microvascular endothelial damage or endotheliitis. In addition, ACE2, a type I transmembrane protein composed of 805 amino acids [54], converts Ang I to Ang-(1–9) and Ang II to Ang-(1–7) [55]. This enzyme pathway that degrades Ang I and Ang II can negatively regulate the activation of RAS and reduce the harmful effects on cerebral blood vessels by inactivating Ang II and forming antagonist peptides [52, 56]. However, when SARS-CoV-2 infection occurs, the combination of SARS-CoV-2 and ACE2 activates the RAS axis, which can directly cause the loss of ACE2 and indirectly lead to the loss of ACE through proteolytic processing and shedding, shifting the balance of ACE/ACE2 towards a higher level of Ang II [57, 58]. This can greatly increase the risk of ischemic stroke in the following two ways. On one hand, increased Ang II blocks blood flow to the brain through the AT1 receptor in the brain, which leads to tissue ischemia, inflammation, oxidative stress, cell damage, and apoptosis. On the other hand, Ang-(1–7), which stimulates Mas receptors to promote cerebral angiogenesis is reduced, resulting in decreased cerebral blood flow, increased oxidative stress, neuroinflammation, and neuronal death [59].

In addition to direct interaction with cerebral blood vessels, SARS-CoV-2 can indirectly cause ischemic stroke by acting on the cardiovascular system. ACE2 receptor is abundantly expressed in myocardium, vascular endothelium, and arterial smooth muscle [60]. SARS-CoV-2 can damage cardiomyocytes through a variety of mechanisms, including direct viral damage, systemic inflammatory response, destabilized coronary plaque, and severe hypoxia, leading to cardiac
dysfunction and arrhythmias [61, 62] and predisposing to thrombogenesis and stroke risk. The baseline level of ACE2 expression in patients with hypertension, cardiovascular disease, and advanced age is reduced, which makes them more susceptible to SARS-CoV-2 mediated ACE/ACE2 imbalance [63]. ACE2 not only protects vascular endothelium and reduce atherosclerosis [64, 65] but also regulates vascular function by regulating nitric oxide release and oxidative stress [66]. When the level of ACE2 expression reduces, vascular endothelium function is impaired, and the balance of ACE/ACE2 tends to be at a higher Ang II level, which may promote thrombosis [67]. ACE metabolizes bradykinin, which causes vasoconstriction and reduces the release of tissue plasminogen activator (t-PA) [68]. Ang II induces endothelial cells to express plasminogen activator inhibitor (PAI) through the AT1 receptor resulting in PAI/t-PA imbalance and a hypercoagulable state [69, 70]. Ang II/AT1 receptor can enhance oxidative stress and inflammation by activating nicotinamide adenine dinucleotide phosphate oxidease. AT1 receptor activates NF-κB and activated protein 1 to initiate transcription of multiple pro-inflammatory genes. AT1 receptor also activates MCP-1 to induce inflammatory cell accumulation, adhesion, and infiltration [51]. Inflammation can aggravate coagulation disorders through the inflammation and coagulation mechanisms mentioned above.

3. Hypoxia

ACE2 is also expressed in the carotid body [71]. Some studies suggest that hypoxia in patients with COVID-19 may be caused by impaired oxygen sensing mechanisms in the carotid body and reduced oxygen transport capacity of the blood [72]. Decreased red blood cell count [73, 74] and low hematocrit [75] can be observed in COVID-19 patients with hypoxia. Two potential mechanisms have been identified: 1) SARS-CoV-2 interacts with hemoglobin molecules through CD147, CD26, and other receptors located in red blood cells and/or blood cell precursors; 2) The effect of hepcidin on viral spike protein can cause blockage of iron transportation [76]. Hypoxia is common in patients with COVID-19 [77–79].

Hypoxia is not only the result of vascular occlusion but local or systemic hypoxia can also stimulate thrombosis [80] and increase its incidence [81, 82]. The brain receives 15% of the total cardiac output and 20% of the body’s oxygen supply. The brain is very susceptible to changes in oxygen levels. Even short-term hypoxia can affect the brain [83]. Hypoxia can increase the expression of ACE, endothelin-1 gene, endothelin A and B receptor mRNAs, and platelet-derived growth factor chain gene in cardiac endothelial cells [84] leading to vascular function disorder. Hypoxia can activate the early growth response 1 transcription factor leading to the de novo transcription/translation of TF in mononuclear phagocytes and smooth muscle cells, which eventually causes fibrin deposition in blood vessels. Hypoxia also upregulates plasminogen activator inhibitor-1 (PAI-1), which in turn amplifies the inhibitory effect on plasmin [85]. In addition, hypoxia can increase the expression of hypoxia-inducible factor (HIF). HIF can directly activate platelets and coagulation factors, increase TF and PAI-1 expression, and inhibit anticoagulant protein S [78]. Hypoxia increases the risk of thrombosis by regulating the coagulation system and fibrinolytic system. Besides, hypoxia can also aggravate inflammation by inducing proinflammatory mediators, such as TNF-α and IL-1, and further aggravate coagulation dysfunction, thereby increasing blood viscosity and hypercoagulability [80]. ACE2 acts as a vasopressor in the lung epithelium and its homologous enzyme, ACE1, acts as a vasoconstrictor. These two enzymes form a balance under normoxic conditions. However, under hypoxic conditions, HIF-1 in pulmonary artery smooth muscle cells can upregulate ACE1 and downregulate ACE2 expression [86], which can cause pulmonary vasoconstriction and further exacerbate hypoxia.

4. Stress disorders

ACE2 in the hypothalamus can suppress stress and anxiety by inhibiting the production of corticotropin-releasing hormone [87] and increasing the production of Ang-(1–7) [88–91]. The decrease in ACE2 caused by SARS-CoV-2 infection affects this regulatory mechanism. The high expression of Ang-II caused by SARS-CoV-2 infection can bind to AT1 receptor in the brain, thereby causing stress-related behaviors, including anxiety, depression, and panic [92]. In addition, during the SARS-CoV-2 pandemic, serious mental health crises have occurred throughout the world [93]. The pressures associated with COVID-19 will continue to exist, including self-isolation, social alienation, unemployment, and disease threats [94]. The pressure and psychological crisis because of COVID-19 will exacerbate the stress disorder.

Multicenter studies have shown that acute stress conditions can cause a sudden stroke. Such patients were first observed in 1956 [95]. Psychological stress is common for up to 1 month before the onset of the illness. Studies have shown that 16.5% of the stroke patients have psychological stress [96]. Psychosocial
pressure leads to an increase in morbidity and mortality of atherosclerotic thrombotic cerebrovascular disease, that is, ischemic stroke, by 1.5 to 2.5 times [97]. Physiological prethrombotic stress response is part of the fight or flight response, but under acute stress, vulnerable individuals with cardiovascular diseases (because of their impaired endothelial function) may have excessive prethrombotic stress response and increases the risk of stress triggering atherosclerotic thrombosis [98]. Acute stress can cause changes in various procoagulant molecules, such as fibrinogen, coagulation factors, platelet activity, thrombin-antithrombin complex, and fibrin protein D-dimer leading to hypercoagulable states. The contributory factors such as advanced age, male gender, cardiovascular disease, and negative emotions, can exacerbate the abovementioned hypercoagulation [99, 100]. Besides, acute stress increases the proinflammatory cytokines in circulation, such as IL-6, TNF-α, and IL-1. Proinflammatory cytokines can also exacerbate the hypercoagulable state. IL-6 is a strong inducer that induces the liver to produce CRP, fibrinogen, and a series of other hematostatic factors [101]. Pathological changes under acute stress greatly increases the risk of ischemic stroke.

The characteristics and pathophysiological changes of patients with coronavirus disease 2019 (COVID-19) infections

| Characteristics       | Pathophysiological Changes                      |
|-----------------------|-------------------------------------------------|
| Abnormal immune response | Inflammation; hypercoagulable state             |
| Renin angiotensin system disorder | Vascular endothelial damage; hemodynamic disorder; hypercoagulable state; inflammation |
| Hypoxia               | Vascular dysfunction; inflammation; hypercoagulable state |
| Stress disorder       | Inflammation; hypercoagulable state             |

Results and discussions

A meta-analysis of 46,248 patients with COVID-19 showed that the most common comorbidities affecting patients are hypertension, diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and cerebrovascular disease, among others [102]. Hypertension (OR: 2.29, \( p < 0.001 \)), diabetes (OR: 2.47, \( p < 0.001 \)), chronic obstructive pulmonary disease (OR: 5.97, \( p < 0.001 \)), cardiovascular disease (OR: 2.93, \( p < 0.001 \)), and cerebrovascular disease (OR: 3.89, \( p = 0.002 \)) were independent risk factors for COVID-19 [103]. Advanced age and these comorbidities were also found to be risk factors for ischemic stroke in COVID-19 patients [104]. The prevalence of ischemic stroke in COVID-19 patients was estimated to be 1.6% (95% CI, 0.8–2.5%) based on a meta-analysis of available cohort studies [6]. Compared to that in the non-COVID-19 cohort, COVID-19-related ischemic stroke patients have increased stroke severity on admission. Studies have suggested that SARS-CoV-2 infection might cause direct vascular disease or enhance the immunogenic thrombosis environment through several mechanisms [105]. The wide range of multi-system complications of COVID-19, including acute respiratory distress syndrome, arrhythmia, shock, pulmonary embolism, cytokine storm, and secondary infection could further exacerbate the adverse consequences of stroke patients, including a higher deaths rate [105].

A study with a sample size of 20 people showed that the mechanisms of COVID-19-related ischemic stroke include cardiac embolism in 40% of cases, small vessel diseases in 5%, other established mechanisms in 20%, and cryptogenic causes in 35%. Of the 11 patients who completed vascular imaging, three (27%) had large vessel occlusion [106]. The pro-inflammatory and hypercoagulable states induced by SARS-CoV-2, which are prone to the formation of embolic stroke and large vessel occlusion-type stroke, are often described in severely ill patients with severe COVID-19 disease [107–109]. Patients with a history of vascular risk factors might have an increased risk of embolic stroke and large vessel occlusive stroke due to complications such as shock, hypotension, arrhythmia, heart failure, and diffuse intravascular coagulation [110]. In addition, studies have reported that COVID-19 patients with cardiovascular comorbidities have multiple cerebral infarctions, with no known extracerebral thrombosis. It could be that SARS-CoV-2 directly infects the cerebral arteries and causes vasculitis and vasospasms. In addition to continuous inflammation, the instability of atherosclerotic plaques and thrombosis lead to the occurrence of multiple cerebral ischemia [111, 112].

Stroke is a symptom of young patients (<50 years old) with mild COVID-19 disease, which has attracted increasing attention [107]. Compared with that in the previous year, the rate of young people suffering from large-vessel stroke has increased by seven-fold, suggesting that SARS-CoV-2 is independently associated with stroke [113]. Further, Oxley et al. recently reported five young COVID-19 patients (average age, 39 years) with no known risk factors, presenting with large vessel occlusion stroke. Arterial dissection might be one of the underlying pathological causes. One of the mechanisms is that the arterial dissection in COVID-19 patients could be secondary to excessive inflammation, which can cause endothelial
dysfunction. Another potential mechanism might be that SARS-CoV-2 directly invades vascular endothelial cells by binding to ACE2 receptors, thereby increasing the chance of vascular endothelial damage [114]. There is one case report showing that a young healthy woman developed cryptogenic stroke. The mechanism might be that SARS-COV-2 directly penetrates the endothelial cells of cerebral cortical arterioles, thereby inducing direct or immune-mediated damage [108]. There are also reports of small ischemic stroke [115], which could be caused by viral cerebral microvascular endotheliitis or systemic inflammation [116].

Limitations
We acknowledge that this review has certain limitations. Firstly, there are currently no relevant animal experiments on the molecular mechanism or pathogenic mechanisms in the context of COVID-19 and ischemic stroke. The research on the relationship between COVID-19 and ischemic stroke is mainly conducted through observational and statistical analyses, e.g. based on clinical manifestations, autopsy, blood tests, and imaging findings. This of course will be biased. Secondly, most of the included studies are case series or case reports; only a few are reports of cohorts, still with limited sizes. Additionally, most of these studies are based on relatively short follow-up times. Of note, the quality of some of the research studies is at least questionable; therefore, there is a high chance of reporting biases. Finally, many reports of ischemic stroke related to COVID-19 may be published in local languages (especially Chinese and Italian). Since this study was only based on publications indexed to PubMed, Web of Science, and other databases dedicated to COVID, biases cannot be ruled out.

Conclusions
There are currently no specific drugs for the management of COVID-19, and most patients with COVID-19 receive antiviral, anti-inflammatory, and support treatments. Many studies have reported ischemic stroke in patients with COVID-19 [5, 117–123]. Ischemic stroke has a high risk of causing disability and is associated with a high mortality rate. This article describes the effects of SARS-CoV-2 and the possible mechanisms that lead to ischemic stroke. It is hoped that when medical staff treat patients with COVID-19 (especially patients with a high risk of ischemic stroke such as the elderly and patients with hypertension, diabetes, and cardiovascular diseases), they would pay attention to the occurrence of ischemic stroke and other thrombotic complications to improve the prognosis of patients with COVID-19.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by the ‘Six Talent Peaks’ project of Jiangsu Province under Grant (No. WSW-246).

ORCID
XiaoJia Tang http://orcid.org/0000-0002-1990-7783

References
[1] Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020;9(1):275–277.
[2] Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
[3] World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
[4] Mohamud AY, Griffith B, Rehman M, et al. Intraluminal carotid artery thrombus in COVID-19: another danger of cytokine storm? AJNR Am J Neuroradiol. 2020;41(9):1677–1682.
[5] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(8):683.
[6] Tsivgoulis G, Katsanos AH, Ornello R, et al. Ischemic stroke epidemiology during the COVID-19 pandemic: navigating uncharted waters with changing tides. Stroke. 2020;51(7):1924–1926.
[7] Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:62–75.
[8] Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181–192.
[9] Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358.
[10] Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
[11] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
[12] Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;588(7836):E6.

[13] Wan Y, Shang J, Graham R, et al. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020;94(7):JVI.00127-20.

[14] Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11.

[15] Baccala R, Gonzalez-Quintial R, Lawson BR, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11.

[16] Nelemans T, Kikkert M. Viral innate immune evasion and the pathogenesis of emerging RNA virus infections. Viruses. 2019;11(10):961.

[17] Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010;84(3):1289–1301.

[18] Manni ML, Robinson KM, Alcorn JF. A tale of two immunity systems: platelets are dynamic sensors and effector cells on the frontline of intravascular thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687–1693.

[19] Eilertsen K-E, Østerud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis. 2004;15(7):521–538.

[20] Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123(17):2605–2613.

[21] Costela-Ruiz VJ, Illsca-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75.

[22] Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. JMRI. 2019;20(14):3394.

[23] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E005.

[24] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069

[25] Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.

[26] Iba T, Levy JH, Warkentin TE. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989–1994.

[27] Hess DC, Eldahshan W, Rutkowski E. COVID-19-related stroke. Transl Stroke Res. 2020;11(3):322–325.

[28] Guo L, Rondina MT. The era of thrombin/infammation: platelets are dynamic sensors and effector cells during infectious diseases. Front Immunol. 2019;10:2204.

[29] Gaertner F, Massberg S. Blood coagulation in immunothrombosis – at the frontline of intravascular immunity. Semin Immunol. 2016;28(6):561–569.

[30] Guitz TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449–2460.

[31] Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19(2):149–154.

[32] Bautista-Vargas M, Bonilla-Abadia F, Cañas CA. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J Thromb Thrombolysis. 2020;50(3):479–483.

[33] Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687–1693.

[34] Zucoloto AZ, Jenne CN. Platelet-neutrophil interplay: insights into neutrophil extracellular trap (NET)-driven coagulation in infection. Front Cardiovasc Med. 2019;6:85.

[35] Han M, Yan W, Huang Y, et al. The nucleocapsid protein of SARS-CoV induces transcription of hif1α in macrophages. J Biochem. 2008;144(1):51–62.

[36] Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34(10):2518–2532.

[37] Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009;105(2):128–137.

[38] Schuett H, Luchtelfeld M, Grothusan C, et al. Much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(8):215–222.

[39] Miwa K, Tanaka M, Okazaki S, et al. Association between interleukin-6 levels and first-ever cerebrovascular events in patients with vascular risk factors. Arterioscler Thromb Vasc Biol. 2013;33(2):400–405.

[40] Cao JJ, Thach C, Manolli TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108(2):166–170.
[44] Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69–71.

[45] Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):32328–32343.

[46] Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2008;107(5):E1–E9.

[47] Komatsu T, Suzuki Y, Imai J, et al. Molecular cloning, mRNA expression and chromosomal localization of mouse angiotensin-converting enzyme-related carboxypeptidase (mACE2). DNA Seq. 2002;13(4):217–220.

[48] Romoli M, Jelicic I, Bernard-Valnet R. A systematic review of neurological manifestations of SARS-CoV-2 infection: the devil is hidden in the details. Eur J Neurol. 2020;27:1712–1726.

[49] Choi JY, Lee HK, Park JH, et al. Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke. Biochem Biophys Res Commun. 2020;528(3):413–419.

[50] Dell’Era V, Farri F, Garzano G, et al. Smell and taste disorders during COVID-19 outbreak: a cross-sectional study on 355 patients. Head & Neck. 2020;42(7):1591–1596.

[51] Kurihara T, Ozawa Y, Ishida S, et al. Renin-angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflam. 2012;2012:581695.

[52] Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439–465.

[53] Kehoe PG, Wong S, Al Mulhim N, et al. Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology. Alz Res Ther. 2016;8(1):50.

[54] Alenina N, Bader M. ACE2 in brain physiology and pathophysiology: evidence from transgenic animal models. Neurochem Res. 2019;44(6):1323–1329.

[55] Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and nephrilysin in angiotensin peptide metabolism. Biochem J. 2004;383(Pt 1):45–51.

[56] Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol. 2008;75(4):781–786.

[57] Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167–173.

[58] Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474.

[59] Kangussu LM, Marzano LAS, Souza CF, et al. The renin-angiotensin system and the cerebrovascular diseases: experimental and clinical evidence. Protein Pept Lett. 2020;27(6):463–475.

[60] Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637.

[61] Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):1–8.

[62] Valderrama EV, Humbert K, Lord A, et al. Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke. Stroke. 2020;51(7):e124–e127.

[63] Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012:256294.

[64] Lovren F, Pan Y, Quan A, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295(4):H1377–H1384.

[65] Thomas MC, Pickering RJ, Tsorto D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res. 2010;107(7):888–897.

[66] Rabelo LA, Todiras M, Nunes-Souza V, et al. Genetic deletion of ACE2 induces vascular dysfunction in C57BL/6 mice: role of nitric oxide imbalance and oxidative stress. PLoS One. 2016;11(4):e0150255.

[67] Dmitrieva NI, Burg MB. Elevated sodium and dehydration stimulate inflammatory signaling in endothelial cells and promote atherosclerosis. PLoS One. 2015;10(6):e0128870.

[68] Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost. 1997;77(03):522–525.

[69] Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95(3):995–1001.

[70] Nakamura S, Nakamura I, Ma L, et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int. 2000;58(1):251–259.

[71] Li YL, Schultz HD. Enhanced sensitivity of Kv channels to hypoxia in the rabbit carotid body in heart failure: role of angiotensin II. J Physiol. 2006;575(Pt 1):215–227.

[72] Soliz J, Schneider-Gasser EM, Arias-Reyes C, et al. Coping with hypoxemia: could erythropoietin (EPO) be an adjuvant treatment of COVID-19. Respir Physiol Neurobiol. 2020;279:103476.

[73] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.

[74] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2
pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.

[75] Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–1379.

[76] Cavezi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020;10(2):1271.

[77] Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239.

[78] Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost. 2020;46(7):772–776.

[79] Kui L, Fang Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025–1031.

[80] Gupta N, Sahu A, Prabhakar A, et al. Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci USA. 2017;114(18):4763–4768.

[81] Prchal JT. Hypoxia and thrombosis. Blood. 2018;132(4):348–349.

[82] Bovill EG, van der Vliet A. Venous valvular stasis and the pathogenesis of ischemia-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73:527–545.

[83] Plant LD, Marks JD, Goldstein SA. SUMOylation of Na(V)1.2 channels mediates the early response to acute hypoxia in central neurons. Elife. 2016;5:e20054.

[84] Sun MK. Hypoxia, ischemic stroke, and memory deficits: prospects for therapy. IUBMB Life. 1999;48(4):373–378.

[85] Yan SF, Mackman N, Kisiel W, et al. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol. 1999;19(9):2029–2035.

[86] Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, et al. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? Respir Physiol Neurobiol. 2020;277:103443.

[87] Wang LA, de Kloet AD, Smeltzer MD, et al. Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 damages stress responsiveness in male mice. Neuropharmacology. 2018;133:85–93.

[88] Walther T, Balschun D, Voigt JP, et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem. 1998;273(19):11867–11873.

[89] Kangussu LM, Almeida-Santos AF, Bader M, et al. Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen. Behav Brain Res. 2013;257:25–30.

[90] Kangussu LM, Almeida-Santos AF, Moreira FA, et al. Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): role of the Mas receptor. Behav Brain Res. 2017;331:193–198.

[91] Moura Santos D, Ribeiro Marins F, Limboco-Filho M, et al. Chronic overexpression of angiotensin-(1-7) in rats reduces cardiac reactivity to acute stress and dampens anxious behavior. Stress. 2017;20(2):189–196.

[92] Armando I, Carranza A, Nishimura Y, et al. Peripheral administration of an angiotensin II AT1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation stress. Endocrinology. 2001;142(9):3880–3889.

[93] Galea S, Merchant RM, Lurie N. The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med. 2020;180(6):817.

[94] Swartz HA. The role of psychotherapy during the COVID-19 pandemic. APT. 2020;73(2):41–42.

[95] Ecker A. Emotional stress before strokes: a preliminary report of 20 cases. Ann Intern Med. 1954;40(1):49–56.

[96] Sharma A, Prasad K, Padma MV, et al. Prevalence of triggering factors in acute stroke: hospital-based observational cross-sectional study. J Stroke Cerebrovasc Dis. 2015;24(2):337–347.

[97] von Känel R. Psychosocial stress and cardiovascular risk: current opinion. Swiss Med Wkly. 2012;142:w13502.

[98] Austin AW, Wissmann T, von Kanel R. Stress and hemostasis: an update. Semin Thromb Hemost. 2013;39(8):902–912.

[99] von Känel R. Acute mental stress and hemostasis: when physiology becomes vascular harm. Thromb Res. 2015;135(Suppl 1):S52–S55.

[100] von Känel R, Mills PJ, Fainman C, et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom Med. 2001;63(4):531–544.

[101] von Känel R, Kudielka BM, Hanebuth D, et al. Different contribution of interleukin-6 and cortisol activity to total plasma fibrin concentration and to acute mental stress-induced fibrin formation. Clin Sci. 2005;109(1):61–67.

[102] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.

[103] Wang B, Li R, Lu Z, et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049–6057.

[104] Allegro A, Innao V, Allegro AG, et al. Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Ann Hematol. 2020;99(9):1953–1965.

[105] Ntafos G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the Global COVID-19 stroke registry. Stroke. 2020;51(9):e254–e88.

[106] Rothstein A, Oldridge O, Schwennesen H, et al. Acute cerebrovascular events in hospitalized COVID-19 patients. Stroke. 2020;51(9):e219–e222.
Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020;382(20):e60.

Frisullo G, Bellavia S, Scala I, et al. Stroke and COVID19: not only a large-vessel disease. J Stroke Cerebrovasc Dis. 2020;29(10):105074.

Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain Behav Immun. 2020;87:115–119.

Fatima N, Saqqur M, Qamar F, et al. Impact of COVID-19 on neurological manifestations: an overview of stroke presentation in pandemic. Neurol Sci. 2020;41(10):2675–2679.

Guillan M, Villacieros-Alvarez J, Bellido S, et al. Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient. Thromb Res. 2020;193:107–109.

Zayet S, Klopfenstein T, Kovács R, et al. Acute cerebral stroke with multiple infarctions and COVID-19, France, 2020. Emerg Infect Dis. 2020;26(9):2258–2260.

Fifi JT, Mocco J. COVID-19 related stroke in young individuals. Lancet Neurol. 2020;19(9):713–715.

Patel P, Khandelwal P, Gupta G, et al. COVID-19 and cervical artery dissection – a causative association? J Stroke Cerebrovasc Dis. 2020;29(10):105047.

Schenck M, Kummerlen C, Collange O, et al. Neurologic features in severe SARS-CoV-2 Infection. N Engl J Med. 2020;382(23):2268–2270.

Singhal AB, Gonzalez RG, Chwalisz BK, et al. Case 26-2020: a 60-year-old woman with altered mental status and weakness on the left side. N Engl J Med. 2020;383(8):764–773.

Duroi I, Van Durme F, Bruyns T, et al. Fatal ischaemic stroke during COVID-19 and acute lung injury. Eur J Case Rep Intern Med. 2020;7(6):001732.

Seabra C, Silva B, Fagundes V, et al. Should the management of embolic stroke in the elderly be changed if they also have COVID-19? Eur J Case Rep Intern Med. 2020;7(6):001736.

Benger M, Williams O, Siddiqui J, et al. Intracerebral haemorrhage (ICH) and COVID-19: clinical characteristics from a case series. Brain Behav Immun. 2020;88:940–944.

Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.

Cantador E, Nuñez A, Sobrino P, et al. Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients. J Thromb Thrombolysis. 2020;50(3):543–547.

García Espinosa J, Moya Sánchez E, Martínez Martínez A. Severe COVID-19 with debut as bilateral pneumonia, ischemic stroke, and acute myocardial infarction. Med Clin. 2020;155(4):188.

Vonck K, Garrez I, De Herdt V, et al. Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2. Eur J Neurol. 2020;27(8):1578–1587.